# Editorial: Non-cutaneous melanoma: new therapeutic insights

**Authors:** Ernesto Rossi, Richard D. Carvajal

PMC · DOI: 10.3389/fonc.2023.1362238 · Frontiers in Oncology · 2024-01-17

## Full-text entities

- **Genes:** MAP2K7 (mitogen-activated protein kinase kinase 7) [NCBI Gene 5609] {aka JNKK2, MAPKK7, MEK, MEK 7, MKK7, PRKMK7}, SUCLG1 (succinate-CoA ligase GDP/ADP-forming subunit alpha) [NCBI Gene 8802] {aka GALPHA, MTDPS9, SUCLA1}, CTLA4 (cytotoxic T-lymphocyte associated protein 4) [NCBI Gene 1493] {aka ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4}, DLL3 [NCBI Gene 105375808], TXK (TXK tyrosine kinase) [NCBI Gene 7294] {aka BTKL, PSCTK5, PTK4, RLK, TKL}, SPATA2 (spermatogenesis associated 2) [NCBI Gene 9825] {aka PD1, PPP1R145, tamo}, PRRT2 (proline rich transmembrane protein 2) [NCBI Gene 112476] {aka BFIC2, BFIS2, DSPB3, DYT10, EKD1, FICCA}, MET (MET proto-oncogene, receptor tyrosine kinase) [NCBI Gene 4233] {aka AUTS9, DA11, DFNB97, HGFR, RCCP2, c-Met}
- **Diseases:** Extracutaneous melanomas (MESH:D008545), cutaneous disease (MESH:D004194), Uveal melanoma (MESH:C536494), metastases (MESH:D009362), cancers (MESH:D009369), Non-cutaneous melanoma (MESH:C562393), primary (MESH:D010538)
- **Chemicals:** temozolomide (MESH:D000077204), binimetinib (MESH:C581313), sotrastaurin (MESH:C543528), crizotinib (MESH:D000077547), HEPZATO KIT (-), selumetinib (MESH:C517975)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC10829762/full.md

## References

19 references — full list in the complete paper: https://tomesphere.com/paper/PMC10829762/full.md

---
Source: https://tomesphere.com/paper/PMC10829762